IP Library Patent Application 11105334
Patent Application
App. No. 11/105,334

Composite bone graft material

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/105,334
Abstract

A bone graft material comprising about 50-90% quickly bioresorbable porogen particles and about 10-50% of a calcium phosphate compound or salt matrix material. A bioactive substance may be included in the matrix material, the porogen particles, or both. Commercial packages containing the bone graft materials and methods for repairing bone therewith are also claimed.

Claims (48)

1 . A bone graft material having a calcium matrix component and porogen particles, present in a porogen particle-to-matrix material ratio of 1:1 to about 9:1.

2 . The bone graft material according to claim 1 , wherein said calcium matrix component comprises calcium sodium phosphate, tricalcium phosphate, dicalcium phosphate dihydrate, calcium hydroxyapatite, or a combination thereof.

3 . The bone graft material according to claim 1 , wherein said calcium matrix component further comprises at least one plasticizing agent, at least one bioactive agent, or a combination thereof.

4 . The bone graft material according to claim 1 , wherein said porogen particles comprise at least one biocompatible, biodegradable substance.

5 . The bone graft material according to claim 4 , wherein said biocompatible, biodegradable substance is osteoinductive demineralized bone matrix (DBM) or an osteoinductive DBM substitute.

6 . The bone graft material according to claim 5 , wherein said DBM is human or bovine DBM and said DBM substitute is osteoinductive-factor-supplemented demineralized mollusk nacre.

7 . The bone graft material according to claim 4 , wherein said biocompatible, biodegradable substance is a biocompatible, biodegradable polymer.

8 . The bone graft material according to claim 7 , wherein said biocompatible, biodegradable polymer is a biocompatible, biodegradable polyester, polyanhydride, tyrosine-derived polycarbonate, polyorthoester, or polymer blend containing at least one such polymer.

9 . The bone graft material according to claim 7 , wherein said biocompatible, biodegradable polymer is a biocompatible, biodegradable polyester.

10 . The bone graft material according to claim 9 , wherein said biocompatible, biodegradable polyester is a biocompatible, biodegradable polyhydroxyalkanoate.

11 . The bone graft material according to claim 10 , wherein said biocompatible, biodegradable polyhydroxyalkanoate is formed from hydroxyl-carboxylic acid monomers independently containing about 2 to about 6 carbon atoms, from lactone forms thereof, or from a combination thereof.

12 . The bone graft material according to claim 11 , wherein the average size of said carboxylic acid monomers is about 2 to about 4 carbon atoms.

13 . The bone graft material according to claim 7 , wherein said biocompatible, biodegradable polymer has a weight average molecular weight of about 2,000 to about 100,000.

14 . The bone graft material according to claim 7 , wherein said biocompatible, biodegradable polymer has a weight average molecular weight of about 20,000 to about 80,000.

15 . The bone graft material according to claim 7 , wherein said biocompatible, biodegradable polymer has a weight average molecular weight of about 50,000 to about 55,000.

16 . The bone graft material according to claim 1 , wherein said porogen particles comprise at least one bioactive agent.

17 . The bone graft material according to claim 1 , wherein said porogen particles comprise at least substantially regular polyhedral, lenticular, ovate, or spherical particles, or a combination thereof.

18 . The bone graft material according to claim 1 , wherein said porogen particles collectively have at least one average axial, transverse, or lateral dimension that is about 100 to about 500 microns.

19 . The bone graft material according to claim 1 , wherein said porogen particles collectively have at least one average axial, transverse, or lateral dimension that is about 120 to about 425 microns.

20 . The bone graft material according to claim 1 , wherein said porogen particles collectively have at least one average axial, transverse, or lateral dimension that is about 120 to about 350 microns.

21 . The bone graft material according to claim 1 , wherein each of the average axial, transverse, and lateral dimensions of the porogen particles is independently about 100 to about 500 microns.

22 . The bone graft material according to claim 1 , wherein each of the average axial, transverse, and lateral dimensions of the porogen particles is independently about 120 to about 425 microns.

23 . The bone graft material according to claim 1 , wherein each of the average axial, transverse, and lateral dimensions of the porogen particles is independently about 120 to about 350 microns.

24 . The bone graft material according to claim 1 , wherein said porogen particles have a ratio of average width to average length that is from about 5:1 to about 1:5.

25 . The bone graft material according to claim 1 , wherein said porogen particles have a ratio of average width to average length that is from about 2:1 to about 1:2.

26 . The bone graft material according to claim 1 , wherein said porogen particles have a ratio of average width to average length that is about 1:1.

27 . The bone graft material according to claim 1 , wherein said porogen particles make up about 50% to about 90% by volume of the bone graft material.

28 . The bone graft material according to claim 1 , wherein said porogen particles make up about 75% to about 90% by volume of the bone graft material.

29 . The bone graft material according to claim 1 , wherein said porogen particles make up about 80% to about 90% by volume of the bone graft material.

30 . The bone graft material according to claim 1 , wherein said porogen particles make up more than 80% to about 90% by volume of the bone graft material.

31 . The bone graft material according to claim 1 , wherein said porogen particles are solid particles.

32 . The bone graft material according to claim 1 , wherein said porogen particles are capable of being biodegraded in vivo in about 10 minutes to about 7 days, or wherein said porogen particles are DBM or DBM substitute porogen particles that are capable of being biodegraded in vivo in about 10 minutes to about 8 weeks, or said porogen particles comprise a combination of these porogen particles.

33 . The bone graft material according to claim 1 , wherein said porogen particles are hollow or laminar particles.

34 . The bone graft material according to claim 33 , wherein at least one wall or layer of said porogen particles is capable of being biodegraded in about 10 minutes to about 7 days, or wherein at least one wall or layer of said porogen particles is DBM or a DBM substitute wall or layer that is capable of being biodegraded in vivo in about 10 minutes to about 8 weeks, or said porogen particles comprise a combination of these hollow or laminar particles.

35 . The bone graft material according to of claim 1 , wherein said material is provided in the form of a paste, injectible solution or slurry, dry powder, or dry solid.

36 . The bone graft material according to claim 1 , wherein said material is provided in the form of a paste, injectible solution or slurry that has been hydrated by application of a neat solution or biological fluid to a dry bone graft material according to claim 1 .

37 . A commercial package containing a bone graft material according to claim 1 and instructions for use thereof in repairing bone.

38 . A method for repairing bone comprising:

providing a bone graft material according to claim 1 , and

administering said bone graft material to a living bone tissue surface in need thereof.

39 . The method according to claim 38 , said method further comprising permitting said material to remain at an in vivo site in which it is placed, for a sufficient time to permit the porogen particles thereof to be biodegraded in vivo.

40 . The bone graft material according to claim 1 , wherein said porogen particles include a plurality of first porogen particles comprising osteoinductive DBM or osteoinductive DBM substitute, and a plurality of second porogen particles comprising a biocompatible, biodegradable polymer or polymers.

41 . The bone graft material according to of claim 30 , wherein said material is provided in the form of a paste, injectible solution or slurry, dry powder, or dry solid.

42 . The bone graft material according to claim 30 , wherein said material is provided in the form of a paste, injectible solution or slurry that has been hydrated by application of a neat solution or biological fluid to a dry bone graft material according to claim 30 .

43 . A commercial package containing a bone graft material according to claim 30 and instructions for use thereof in repairing bone.

44 . A method for repairing bone comprising:

providing a bone graft material according to claim 30 , and

administering said bone graft material to a living bone tissue surface in need thereof.

Assignments (5)
RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 020362/ FRAME 0001 Recorded Nov 23, 2015
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: LVB ACQUISITION, INC.; BIOMET, INC.
Reel/Frame 037155/0133 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR INCORRECTLY IDENTIFIED AS EBI, INC. ON ORIGINAL RECORDATION COVERSHEET SHOULD HAVE BEEN IDENTIFIED AS EBI, L.P. PREVIOUSLY RECORDED ON REEL 021387 FRAME 0450. ASSIGNOR(S) HEREBY CONFIRMS THE ORIGINAL CONVEYANCE TEXT APPEARING IN NAME CHANGE DOCUMENTATION REFLECTS EBI, L.P. IS NOW KNOWN AS EBI, LLC.. Recorded May 26, 2009
From: EBI, L.P.
To: EBI, LLC
Reel/Frame 022727/0859 →
CHANGE OF NAME Recorded Aug 14, 2008
From: EBI, INC.
To: EBI, LLC
Reel/Frame 021387/0450 →
SECURITY AGREEMENT Recorded Dec 10, 2007
From: LVB ACQUISITION, INC.; BIOMET, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT FOR THE SECURED PARTIES
Reel/Frame 020362/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2006
From: SIMON, BRUCE J.; RONK, ROBERT M.; D'ANTONIO, PAUL; SCHWARDT, JEFFREY D.
To: EBI, L.P.
Reel/Frame 017558/0649 →